NeuroPsyCAD

Palestinian Territories
Al Buwayrah, West Bank, Palestinian Territory, 4700-034

Company profile

NeuroPsyCAD company profile

NeuroPsyCAD provides clinicians with patient-personalized reports for early and accurate diagnoses of neuropsychiatric disorders. NeuroPsyCAD's analysis pipeline is automated, with a report being produced in a few hours since they receive the patient's data. Given the high sensitivity and specificity of our approach, subtle changes in brain structure and function can be detected early and accurately at the disease onset, enabling clinicians to diagnose and, thus, treat patients earlier and with more confidence. NeuroPsyCAD aims to replace the so far relatively subjective and metrics-independent practice of psychiatry and neurology with a more quantified, objective, accurate, and personalize one.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
101-250 employees
Founded
2017-05-09

Headquarters

Postal code
4700-034
Country code
PS
Continent
Asia

Capital profile

Funding and company signals

Funding stage
Seed
Funding rounds
2
Last funding
Seed / 2019-01-01
Last equity funding
Seed
Investors
2
Lead investors
1
Founders
4

Founders and investors

Founders

Diana PrataHugo Alexandre FerreiraMaria CosteiraRicardo Maximiano

Lead investors

EISMEA

Investors

EISMEAStartup Braga